Blog

Next >
Erin Newburn, MS, PhD

The Battle Continues: Facing the obstacle of tumor resistance to immunotherapy treatment

December 10th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Erin Newburn, MS, PhD

Five unanswered questions regarding personalized neoantigen cancer vaccines

July 23rd, 2018
by: Erin Newburn, MS, PhD
READ MORE
Erin Newburn, MS, PhD

Comparing and contrasting CTLA-4 and PD-L1/PD-1: A tale of two immune checkpoint inhibitors

May 16th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Erin Newburn, MS, PhD

Understanding the role of HLA in Cancer Immunotherapy

March 5th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Erin Newburn, MS, PhD

Can gene and variant expression from RNASeq be done well using FFPE specimens?

January 24th, 2018
by: Erin Newburn, MS, PhD
As immunotherapy translational research studies using RNA data provide new clues to patient response, identifying the upfront technical factors affecting success is vital.READ MORE
Next >